1-(2-Fluoro-5-nitrophenyl)-1h-pyrrole-2,5-dione | 5375-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: 1-(2-Fluoro-5-nitrophenyl)-1h-pyrrole-2,5-dione
• 英文别名: 1-(2-fluoro-5-nitrophenyl)pyrrole-2,5-dione
• CAS: 5375-19-9
• 化学式: C10H5FN2O4
• mdl: MFCD01156630
• 分子量: 236.16
• InChiKey: QKTMKNLRVMNCGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases
  申请人：Ansorge Siegfried

  公开号：US20070037752A1

  公开（公告）日：2007-02-15

  The invention relates to substances which specifically inhibit peptidases splitting ala-p-nitroanilide for use in medicine. The invention further relates to the use of at least one such substance or of a pharmaceutical or cosmetic composition containing at least one such substance for the prophylaxis and therapy of diseases, in particular the prophylaxis and therapy of diseases with an overshooting immune response (autoimmune diseases, allergies and transplant rejections), of other chronic inflammatory diseases, neuronal diseases and brain damages, skin diseases (acne and psoriasis, among others), tumor diseases and special virus infections (including SARS).
• Method of Treating Kcnq Related Disorders Using Organozinc Compounds
  申请人：Li Min

  公开号：US20110257146A1

  公开（公告）日：2011-10-20

  The instant invention describes methods of treating KCNQ related diseases and disorders using organozinc compounds. In certain embodiments, pain is treated using Zinc Pyrithione.
• Methods and Compositions for Modulating Rad51 and Homologous Recombination
  申请人：The University of Chicago

  公开号：US20140142103A1

  公开（公告）日：2014-05-22

  The present invention concerns methods and compositions involving inhibitors and enhancers of RAD51, a protein involved in homologous recombination. In some embodiments, the present invention concerns methods for stimulating homologous recombination, which has a number of significant research and clinical applications. In certain other embodiments, there are methods for protecting cells using a compound that enhances RAD51 activity. Such enhancers may also be employed to prevent or reduce damage to cells that may be caused by DNA damaging agents. In other embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 enhancer or inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.
• US9198914B2
  申请人：——

  公开号：US9198914B2

  公开（公告）日：2015-12-01